honokiol

11/01/2010 - "Topical treatment of mice with honokiol in a hydrophilic cream-based topical formulation before or after UVB (180 mJ/cm(2)) irradiation resulted in a significant protection against photocarcinogenesis in terms of tumor multiplicity (28-60%, P < 0.05 to <0.001) and tumor volume per tumor-bearing mouse (33-80%, P < 0.05 to 0.001, n = 20). "
05/01/2013 - "Honokiol and its targets of action may be helpful in the development of effective analogs and targeted cancer therapy. "
07/01/2012 - "We investigated the efficacy of honokiol in mice harboring tumors of HTLV-1-infected T-cell origin. "
06/01/2012 - "In the dose-response study, honokiol (30, 45, and 60 μg) significantly decreased skin tumor multiplicity by 36-78% in a dose-dependent manner, while tumor area was reduced by 76-94%. "
11/01/2011 - "This study was designed to test the hypothesis that honokiol enhances the radiosensitivity of cancer cells with mismatch repair defect (HCT116) compared with those that are mismatch repair proficient (HCT116-CH3). "

05/21/2009 - "In conclusion, the present study demonstrates for the first time that honokiol exhibits protective effects against eccentric exercise-induced skeletal muscle damage in rats, probably by modulating inflammation-mediated damage to muscle cells."
01/01/2015 - "Adhesion and inflammation scores were significantly lower in the honokiol group compared with the saline and control groups (p < 0.008). "
04/01/2014 - "Here, we used an in vitro model of cartilage inflammation to investigate the therapeutic potential of honokiol in OA. "
05/01/2012 - "Honokiol, a low-molecular-weight natural product, possesses the ability of anti-inflammation and apoptosis induction. "
01/01/2012 - "Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner."

09/01/2014 - "Honokiol (HNK), derived from the bark of an oriental medicinal plant (Magnolia officinalis), is a promising anticancer agent with preclinical in vitro (PC-3 and LNCaP cells) and in vivo (PC-3 xenografts) efficacy against prostate cancer. "
02/15/2008 - "This study was undertaken to determine the efficacy of honokiol, a constituent of oriental medicinal herb Magnolia officinalis, against human prostate cancer cells in culture and in vivo. "
10/01/2007 - "In conclusion, the present study reveals that the honokiol-mediated G0-G1 phase cell cycle arrest in human prostate cancer cells is associated with the suppression of protein level/phosphorylation of Rb leading to inhibition of transcriptional activity of E2F1."
04/01/2014 - "We have shown previously that honokiol (HNK), a bioactive component of the medicinal plant Magnolia officinalis, inhibits growth of human prostate cancer cells in vitro and in vivo. "
02/15/2008 - "Exposure of human prostate cancer cells (PC-3, LNCaP, and C4-2) to honokiol resulted in apoptotic DNA fragmentation in a concentration- and time-dependent manner irrespective of their androgen responsiveness or p53 status. "

06/01/2011 - "Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro."
01/01/2015 - "Similarly, fibrosis score was significantly lower in the honokiol group compared with the saline group (p < 0.008). "
06/01/2011 - "Honokiol may become a therapeutic agent to prevent renal fibrosis."
06/01/2011 - "Honokiol treatment attenuated tubulointerstitial fibrosis and expression of pro-fibrotic factors in the UUO model. "
06/01/2011 - "Honokiol slowed development of renal fibrosis both in vivo and in vitro. "

10/01/2012 - "Honokiol, a constituent of Magnolia obovata, has various pharmacological effects, including protection against cerebral ischemia. "
10/01/2012 - "However, few studies have been conducted to evaluate the possible neuroprotective effects of honokiol against cerebral ischemia. "
02/01/2003 - "This study suggests that honokiol is a potent neuroprotective agent in focal cerebral ischemia. "
02/08/2013 - "Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF-κB activation and cytokine production of glial cells."
01/23/2013 - "In conclusion, honokiol has a therapeutic window of at least 5h after the onset of cerebral ischemia or 3h after reperfusion in rats, which may be in part ascribed to the disruption of the PSD95-nNOS interaction leading to the inhibition of neurotoxic NO production."